Scarica l'app Stockscreener
42.59
4.25%
-1.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$44.48
Aprire:
$44.4
Volume 24 ore:
614.56K
Relative Volume:
0.78
Capitalizzazione di mercato:
$3.93B
Reddito:
$522.75M
Utile/perdita netta:
$-558.99M
Rapporto P/E:
-6.5827
EPS:
-6.47
Flusso di cassa netto:
$-439.53M
1 W Prestazione:
+0.24%
1M Prestazione:
+3.17%
6M Prestazione:
-25.35%
1 anno Prestazione:
-11.60%
Intervallo 1D:
$42.54
$45.00
Intervallo di 1 settimana:
$42.54
$45.00
Portata 52W:
$37.02
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Confronta RARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
42.59 | 3.93B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright maintains Buy on Ultragenyx with $95 target By Investing.com - Investing.com Australia
Ultragenyx granted FDA priority review for gene therapy in rare brain disorder - MSN
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Reports Strong Growth Amid Challenges - TipRanks
Ultragenyx Pharmaceutical Inc. SEC 10-K Report - TradingView
Inside Ultragenyx's Latest Executive Compensation Package: New Hires Receive Strategic RSU Grants - StockTitan
Canaccord Genuity Group Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $136.00 - MarketBeat
H.C. Wainwright maintains Buy on Ultragenyx with $95 target - Investing.com India
Peregrine Capital Management LLC Acquires 29,684 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Trend Tracker for (RARE) - Stock Traders Daily
Ultragenyx's SWOT analysis: rare disease biotech stock eyes pivotal year By Investing.com - Investing.com South Africa
Canaccord raises Ultragenyx target to $136, keeps Buy rating By Investing.com - Investing.com Australia
Ultragenyx stock gains on FDA priority review (RARE:NASDAQ) - Seeking Alpha
Canaccord raises Ultragenyx target to $136, keeps Buy rating - Investing.com India
Ultragenyx Announces FDA Acceptance and Priority Review of - GlobeNewswire
Ultragenyx's Revolutionary Gene Therapy for Fatal Childhood Disease Advances: FDA Fast-Tracks Review - StockTitan
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from HC Wainwright - MarketBeat
Ultragenyx's SWOT analysis: rare disease biotech stock eyes pivotal year - Investing.com India
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript - Insider Monkey
Ultragenyx Pharmaceutical: Strong Growth Prospects and Pipeline Advancements Reinforce Buy Rating - TipRanks
Ultragenyx stock holds Buy rating, $140 target from Truist - MSN
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN
Goldman Sachs maintains buy on Ultragenyx, target at $78 - MSN
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - MSN
Cantor Fitzgerald maintains $118 target on Ultragenyx stock - MSN
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views - Benzinga
Cantor Fitzgerald maintains $118 target on Ultragenyx stock By Investing.com - Investing.com Nigeria
Goldman Sachs maintains buy on Ultragenyx, target at $78 By Investing.com - Investing.com South Africa
Ultragenyx stock holds Buy rating, $140 target from Truist By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highl - GuruFocus.com
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx: Q4 Earnings Snapshot - The Herald Review
Ultragenyx Pharmaceutical Reports Strong 2024 Growth - TipRanks
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
2 Anti-Kickback Developments Hold Lessons For Biopharma - Law360
ULTRAGENYX PHARMACEUTICAL Earnings Results: $RARE Reports Quarterly Earnings - Nasdaq
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Nasdaq
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):